Researchers have developed a genetically modified version of the herpes virus that infects cancer cells and expresses cytokines that recruit immune cells. When tested in a Phase 2 trial, the virus doubled the response rate when added to standard of care.

See the source article by following the link below:
Researchers have developed a genetically modified version of the herpes virus that infects cancer cells and expresses cytokines that recruit immune cells. When tested in a Phase 2 trial, the virus doubled the response rate when added to standard of care.